Guides
Guide RNA is a piece of RNA that functions as a guide for targeting certain Genome Editor enzymes for gene and genome editing. This page contains information about guide RNAs used and developed by SCGE consortium projects.
246 results in Guides
3849 45-5'Guide - [In Vitro] [Delivery Systems Initiative] [Human]Show Experiments (1)
Peptide Shuttle optimization to deliver Cas12a RNP to human airway epithelia cells
|
3849 C>T lociGuide - [In Vitro] [Collaborative Opportunity Fund] [Human] |
AAVS1_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_10Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_11Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_12Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_13Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
AAVS1_site_14Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
ABE8e-Cas12a Guide 1 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 10 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 11 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 2 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 3 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 4 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 5 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 6 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 7 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 8 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas12a Guide 9 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 1 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 10 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 2 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 3 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 4 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 5 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 6 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 7 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 8 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
ABE8e-Cas9 Guide 9 CCR5 RhesusGuide - [In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque]Show Experiments (1) |
Ai14 gRNAGuide - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
Ai9 SaCas9 Guide AGuide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
Ai9 SaCas9 Guide BGuide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
B2MGuide - [In Vitro] [Collaborative Opportunity Fund] [Human] |
B2M_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
B2M_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
B2M_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
B2M_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
B2M_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
B2M_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
B2M_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
BCM_ssAAV5-Sa_sgBGuide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
BCM_ssAAV5-Sp_sgAGuide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
BCM_ssAAV5-Sp_sgBGuide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
CBLB_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CBLB_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CBLB_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CBLB_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CBLB_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_11Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_13Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_14Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_15Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CCR5_site_16Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_10Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_11Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_12Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CTLA4_site_13Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_10Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
CXCR4_site_11Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Cas12j-GFP1 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP1 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP10 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP10 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP11 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP12 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP13 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP14 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP14 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP15 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP16 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP17 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP18 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP19 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP2 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP2 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP20 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP21 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP22 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP23 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP3 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP3 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP4 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP4 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP5 (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP5 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP5 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP6 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP6 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP7 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP7 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP8 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP8 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP9 (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
Cas12j-GFP9 (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
DMD low gRNA-1Guide - [In Vitro] [Biological Effects Initiative] [Human]Show Experiments (1)
Delivery of saCas9 and gRNAs to nephron epithelia by AAV2 in kidney organoids.
|
DMD low gRNA-2Guide - [In Vitro] [Biological Effects Initiative] [Human] |
FAS_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
FAS_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
FAS_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
FAS_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
FAS_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
GER10-ABE-REVGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse]Show Experiments (1)
Validating Gene Editing Reporter 10 (GER10) Mouse Model in Heterozygous Blastocysts
|
GER12-g1-FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse]Show Experiments (1)
Validating Gene Editing Reporter 12 (GER12) Mouse Model in Heterozygous Blastocysts
|
GER12-g2-FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse]Show Experiments (1)
Validating Gene Editing Reporter 12 (GER12) Mouse Model in Heterozygous Blastocysts
|
GER14-g1-Cpf1-FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse]Show Experiments (1)
Validating Gene Editing Reporter 14 (GER14) Mouse Model in Heterozygous Blastocysts
|
GER14-g1-SaC9-FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse]Show Experiments (1)
Validating Gene Editing Reporter 14 (GER14) Mouse Model in Heterozygous Blastocysts
|
GER14-g1-SpC9-FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse]Show Experiments (1)
Validating Gene Editing Reporter 14 (GER14) Mouse Model in Heterozygous Blastocysts
|
GER18/19 gRNA2 FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
GER18/19 gRNA3 FWDGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
L1-modifiedGuide - [In Vivo, In Vitro] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse]Show Experiments (3)
Testing gRNA sequence and gRNA scaffold modified in Ai9 mice.
|
L1-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
L2-modifiedGuide - [In Vivo, In Vitro] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
L2-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
L3-modifedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
L3-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
LAG3_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
LAG3_site_10Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
McCray_CFTR_Cas9_Guide1Guide - [In Vitro] [Delivery Systems Initiative] [Human]Show Experiments (1)
Peptide Shuttle optimization to deliver Cas9 RNP to human airway epithelia cells
|
NKG2AGuide - [In Vitro] [Delivery Systems Initiative] [Human]Show Experiments (1)
Gene editing in vitro by various peptide variants delivering Cas12a in NK cells.
|
Negative control gRNAGuide - [In Vitro] [Collaborative Opportunity Fund] [Human] |
Negative control gRNAGuide - [In Vitro] [Collaborative Opportunity Fund] [Human] |
PDCD1_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_10Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_11Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_12Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_13Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_14Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_15Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PDCD1_site_16Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN2_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN2_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN2_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_06Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_07Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_08Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
PTPN6_site_09Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Pcsk9 Exon 1 splice domainGuide - [In Vivo] [Small Animal Testing Center (SATC), Delivery Systems Initiative] [Mouse] |
R1-modifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
R1-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
R2-modifiedGuide - [In Vivo, In Vitro] [Delivery Systems Initiative] [Mouse] |
R2-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
R26-1Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
R26-2Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
R26-3Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
R26-52Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
R26-59Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
R26-69Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
STS118 (TLR-MCV1a; Sp_t2-PS:Sp_c20_TLR_MCV1a)Guide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
STS118 (TLR-MCV1a; Sp_t2:Sp_c20_TLR_MCV1a)Guide - [In Vitro] [Delivery Systems Initiative] [Human] |
STS119 (TLR-MCV1b; Sp_t2:Sp_c20_TLR_MCV1b)Guide - [In Vitro] [Delivery Systems Initiative] [Human] |
STS120 (TLR1; Sp_t2:Sp_c20_TLR1)Guide - [In Vitro] [Delivery Systems Initiative] [Human] |
STS134 (PCSK9b; Sp_t2:Sp_c20_PCSK9b)Guide - [In Vitro] [Delivery Systems Initiative] [Mouse]Show Experiments (1)
Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
|
STS135 (PCSK9c; Sp_t2:Sp_c20_PCSK9c)Guide - [In Vitro] [Delivery Systems Initiative] [Mouse]Show Experiments (1)
Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
|
STS159 (mTmG; Sp_t2-PS:Sp_c0_mTmG)Guide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
STS159 (mTmG; Sp_t2-PS:Sp_c20_mTmG)Guide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
STS159 (mTmG; Sp_t2:Sp_c0_mTmG)Guide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
STS159 (mTmG; Sp_t2:Sp_c20_mTmG)Guide - [In Vivo, In Vitro] [Delivery Systems Initiative] [Mouse]Show Experiments (3)
Testing newly chemically modified crRNA and tracrRNA in mTmG mouse embryonic fibroblasts
|
STS204 (DNMT1; Sp_t2:Sp_c20_Dnmt1)Guide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
STS204 (DNMT1; Sp_t41:Sp_c20_Dnmt1)Guide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
STS205 (BACE1; Sp_t41:Sp_c20_Bace1)Guide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
STS96 (PCSK9a; Sp_t2:Sp_c20_PCSK9a)Guide - [In Vitro] [Delivery Systems Initiative] [Mouse]Show Experiments (1)
Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
|
SaC9-g1Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
SaC9-g2Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
SaC9-g3Guide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
SaLoxP1-modifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
SaLoxP1-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
SaLoxP2-modifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
SaLoxP2-unmodifiedGuide - [In Vitro] [Delivery Systems Initiative] [Mouse] |
Sa_Ai9_LGuide - [In Vivo] [Delivery Systems Initiative] [Mouse]Show Experiments (1) |
Sa_Ai9_RGuide - [In Vivo] [Delivery Systems Initiative] [Mouse]Show Experiments (1) |
SapI-GG stuffer (CasĪ¦-1)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
SapI-GG stuffer (CasĪ¦-2)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
SapI-GG stuffer (CasĪ¦-3)Guide - [In Vitro] [Genome Editors] [Human]Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
SpyCas9 g-loxP2_C9Guide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
TLR7-g2-REVGuide - [In Vitro] [Small Animal Testing Center (SATC)] [Mouse] |
TRAC_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
TRAC_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
TRAC_site_03Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
TRAC_site_04Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
TRAC_site_05Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
TRBC1_site_01Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
TRBC1_site_02Guide - [In Vitro] [Biological Systems] [Human]Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
g-loxP2_C9Guide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
g-loxPbot_C12aGuide - [In Vivo] [Delivery Systems Initiative] [Mouse] |
gRNA #8Guide - [In Vivo, In Vitro] [Collaborative Opportunity Fund] [Rhesus macaque] |
sg298Guide - [In Vivo, In Vitro] [Collaborative Opportunity Fund, Delivery Systems Initiative] [Human, Mouse]Show Experiments (3)
Testing new LNPs (lipid nanoparticles) for delivery of Cas9 mRNA/sgRNA in primary fibroblast cells from adult Ai14 mouse cochlea
|
sg298Guide - [In Vivo] [Small Animal Testing Center (SATC)] [Mouse] |
sgAi9LGuide - [In Vivo, In Vitro] [Delivery Systems Initiative] [Human, Mouse] |
sgAi9RGuide - [In Vivo, In Vitro] [Delivery Systems Initiative] [Human, Mouse] |
246 results in Guides
Organism | Compatibility | Name | Description | Source | View Associated.. |
---|---|---|---|---|---|
Human | AsCas12a> | 3849 45-5' | Targets endogenous human locus | IDT |
Show Experiments (1)
Peptide Shuttle optimization to deliver Cas12a RNP to human airway epithelia cells
|
Human | SpyCas9> | 3849 C>T loci | IDT | ||
Human | SpyCas9> | AAVS1_site_01 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_02 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_03 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_04 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_05 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_06 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_07 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_08 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_09 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_10 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_11 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_12 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_13 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | AAVS1_site_14 | Targets AAVS1 safe harbor locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 1 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 10 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 11 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 2 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 3 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 4 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 5 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 6 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 7 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 8 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | LbCas12a> | ABE8e-Cas12a Guide 9 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 1 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 10 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 2 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 3 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 4 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 5 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 6 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 7 CCR5 Rhesus |
Show Experiments (1) |
||
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 8 CCR5 Rhesus | David Liu lab's plasmid clone |
Show Experiments (1) |
|
Rhesus macaque | SpyCas9> | ABE8e-Cas9 Guide 9 CCR5 Rhesus |
Show Experiments (1) |
||
Mouse | SpyCas9> | Ai14 gRNA | This sgRNA targets the Ai9 and related transgenes at multiple sites | IDT | |
Mouse | SauCas9> | Ai9 SaCas9 Guide A | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | Ai9 SaCas9 Guide B | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Human | SpyCas9> | B2M | IDT | ||
Human | SpyCas9> | B2M_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | B2M_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | B2M_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | B2M_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | B2M_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | B2M_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | B2M_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Mouse | SauCas9> | BCM_ssAAV5-Sa_sgB | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SpyCas9> | BCM_ssAAV5-Sp_sgA | This sgRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SpyCas9> | BCM_ssAAV5-Sp_sgB | This sgRNA targets the Ai9 and related transgenes | Vector encoded | |
Human | SpyCas9> | CBLB_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CBLB_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CBLB_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CBLB_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CBLB_site_09 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_09 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_11 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_13 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_14 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_15 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CCR5_site_16 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_09 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_10 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_11 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_12 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CTLA4_site_13 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_10 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | CXCR4_site_11 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | CasĪ¦-1> | Cas12j-GFP1 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP1 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP10 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP10 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP11 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP12 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP13 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP14 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP14 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP15 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP16 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP17 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP18 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP19 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP2 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP2 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP20 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP21 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP22 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP23 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP3 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP3 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP4 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP4 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-1> | Cas12j-GFP5 (CasĪ¦-1) | Guide targeting eGFP compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP5 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP5 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP6 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP6 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP7 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP7 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP8 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP8 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | Cas12j-GFP9 (CasĪ¦-2) | Guide targeting eGFP compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | Cas12j-GFP9 (CasĪ¦-3) | Guide targeting eGFP compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | SpyCas9> | Cas9-CFTR-R553X | CFTR-R553X | IDT | |
Human | SauCas9> | DMD low gRNA-1 | One of two low-off target gRNAs delivred by dual gRNA AAV vector pAAV[2gRNA]-mCherry-U6>{SagRNA#1*}:{SagRNA#2} | VectorBuilder |
Show Experiments (1)
Delivery of saCas9 and gRNAs to nephron epithelia by AAV2 in kidney organoids.
|
Human | SauCas9> | DMD low gRNA-2 | One of two low-off target gRNAs delivred by dual gRNA AAV vector AAV-gRNA | VectorBuilder | |
Human | SpyCas9> | FAS_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | FAS_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | FAS_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | FAS_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | FAS_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Mouse | SpyCas9> | GER10-ABE-REV | sgRNA target sequence for A base editor in Venus | IDT |
Show Experiments (1)
Validating Gene Editing Reporter 10 (GER10) Mouse Model in Heterozygous Blastocysts
|
Mouse | SpyCas9> | GER12-g1-FWD | IDT |
Show Experiments (1)
Validating Gene Editing Reporter 12 (GER12) Mouse Model in Heterozygous Blastocysts
|
|
Mouse | SpyCas9> | GER12-g2-FWD | IDT |
Show Experiments (1)
Validating Gene Editing Reporter 12 (GER12) Mouse Model in Heterozygous Blastocysts
|
|
Mouse | AsCas12a> | GER14-g1-Cpf1-FWD | IDT |
Show Experiments (1)
Validating Gene Editing Reporter 14 (GER14) Mouse Model in Heterozygous Blastocysts
|
|
Mouse | SauCas9> | GER14-g1-SaC9-FWD | lab IVT |
Show Experiments (1)
Validating Gene Editing Reporter 14 (GER14) Mouse Model in Heterozygous Blastocysts
|
|
Mouse | SpyCas9> | GER14-g1-SpC9-FWD | IDT |
Show Experiments (1)
Validating Gene Editing Reporter 14 (GER14) Mouse Model in Heterozygous Blastocysts
|
|
Mouse | SpyCas9> | GER18/19 gRNA2 FWD | 5' guide flanking IVS2-654 C>T mutation | IDT | |
Mouse | SpyCas9> | GER18/19 gRNA3 FWD | 3' guide flanking IVS2-654 C>T mutation | IDT | |
Mouse | SauCas9> | L1-modified | This gRNA targets the Ai9 and related transgenes | Vector encoded |
Show Experiments (3)
Testing gRNA sequence and gRNA scaffold modified in Ai9 mice.
|
Mouse | SauCas9> | L1-unmodified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | L2-modified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | L2-unmodified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | L3-modifed | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | L3-unmodified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Human | SpyCas9> | LAG3_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_09 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | LAG3_site_10 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | McCray_CFTR_Cas9_Guide1 | Targets endogenous human locus | IDT |
Show Experiments (1)
Peptide Shuttle optimization to deliver Cas9 RNP to human airway epithelia cells
|
Human | AsCas12a> | NKG2A | gRNA targeting human NKG2A exon 3 | IDT |
Show Experiments (1)
Gene editing in vitro by various peptide variants delivering Cas12a in NK cells.
|
Human | SpyCas9> | Negative control gRNA | Negative control guide RNA avoid any targets in human/mouse/rat | IDT | |
Human | SpyCas9> | Negative control gRNA | Negative control guide RNA avoid any targets in human/mouse/rat | IDT | |
Human | SpyCas9> | PDCD1_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_09 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_10 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_11 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_12 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_13 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_14 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_15 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PDCD1_site_16 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN2_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN2_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN2_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_06 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_07 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_08 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | PTPN6_site_09 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Mouse | SpyCas9> | Pcsk9 Exon 1 splice domain | Pcsk9 Exon 1 splice domain | Synthego | |
Mouse | SauCas9> | R1-modified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | R1-unmodified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | R2-modified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SauCas9> | R2-unmodified | This gRNA targets the Ai9 and related transgenes | Vector encoded | |
Mouse | SpyCas9> | R26-1 | IDT | ||
Mouse | SpyCas9> | R26-2 | IDT | ||
Mouse | SpyCas9> | R26-3 | IDT | ||
Mouse | SpyCas9> | R26-52 | IDT | ||
Mouse | SpyCas9> | R26-59 | IDT | ||
Mouse | SpyCas9> | R26-69 | IDT | ||
Mouse | SpyCas9> | STS118 (TLR-MCV1a; Sp_t2-PS:Sp_c20_TLR_MCV1a) | Targets traffic light reporter transgene, CY3 labeled | in house production | |
Human | SpyCas9> | STS118 (TLR-MCV1a; Sp_t2:Sp_c20_TLR_MCV1a) | Targets traffic light reporter transgene | in house production | |
Human | SpyCas9> | STS119 (TLR-MCV1b; Sp_t2:Sp_c20_TLR_MCV1b) | Targets traffic light reporter transgene | in house production | |
Human | SpyCas9> | STS120 (TLR1; Sp_t2:Sp_c20_TLR1) | Targets traffic light reporter transgene | in house production | |
Mouse | SpyCas9> | STS134 (PCSK9b; Sp_t2:Sp_c20_PCSK9b) | Targets endogenous mouse locus | in house production |
Show Experiments (1)
Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
|
Mouse | SpyCas9> | STS135 (PCSK9c; Sp_t2:Sp_c20_PCSK9c) | Targets endogenous mouse locus | in house production |
Show Experiments (1)
Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
|
Mouse | SpyCas9> | STS159 (mTmG; Sp_t2-PS:Sp_c0_mTmG) | This sgRNA targets the mTmG transgene | in house production | |
Mouse | SpyCas9> | STS159 (mTmG; Sp_t2-PS:Sp_c20_mTmG) | This sgRNA targets the mTmG transgene | in house production | |
Mouse | SpyCas9> | STS159 (mTmG; Sp_t2:Sp_c0_mTmG) | This sgRNA targets the mTmG transgene | in house production | |
Mouse | SpyCas9> | STS159 (mTmG; Sp_t2:Sp_c20_mTmG) | This sgRNA targets the mTmG transgene | in house production |
Show Experiments (3)
Testing newly chemically modified crRNA and tracrRNA in mTmG mouse embryonic fibroblasts
|
Mouse | SpyCas9> | STS204 (DNMT1; Sp_t2:Sp_c20_Dnmt1) | For endogenous locus | in house production | |
Mouse | SpyCas9> | STS204 (DNMT1; Sp_t41:Sp_c20_Dnmt1) | Targets endogenous mouse locus | in house production | |
Mouse | SpyCas9> | STS205 (BACE1; Sp_t41:Sp_c20_Bace1) | Targets endogenous mouse locus | in house production | |
Mouse | SpyCas9> | STS96 (PCSK9a; Sp_t2:Sp_c20_PCSK9a) | Targets endogenous mouse locus | in house production |
Show Experiments (1)
Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
|
Mouse | SauCas9> | SaC9-g1 | |||
Mouse | SauCas9> | SaC9-g2 | |||
Mouse | SauCas9> | SaC9-g3 | |||
Mouse | SauCas9> | SaLoxP1-modified | This gRNA targets the mTmG, Ai9 and related transgenes at two sites | Vector encoded | |
Mouse | SauCas9> | SaLoxP1-unmodified | This gRNA targets the mTmG, Ai9 and related transgenes at two sites | Vector encoded | |
Mouse | SauCas9> | SaLoxP2-modified | This gRNA targets the mTmG, Ai9 and related transgenes at two sites | Vector encoded | |
Mouse | SauCas9> | SaLoxP2-unmodified | This gRNA targets the mTmG, Ai9 and related transgenes at two sites | Vector encoded | |
Mouse | SauCas9> | Sa_Ai9_L | This gRNA targets the Ai9 and related transgenes, has modified scaffold (Tabebordbar Science 2016) |
Show Experiments (1) |
|
Mouse | SauCas9> | Sa_Ai9_R | This gRNA targets the Ai9 and related transgenes, has modified scaffold (Tabebordbar Science 2016) |
Show Experiments (1) |
|
Human | CasĪ¦-1> | SapI-GG stuffer (CasĪ¦-1) | Non-targeting guide RNA targeting compatible with CasĪ¦-1 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-2> | SapI-GG stuffer (CasĪ¦-2) | Non-targeting guide RNA targeting compatible with CasĪ¦-2 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Human | CasĪ¦-3> | SapI-GG stuffer (CasĪ¦-3) | Non-targeting guide RNA targeting compatible with CasĪ¦-3 |
Show Experiments (1)
Testing newly discovered Biggie Phage editors in human cells
|
|
Mouse | SpyCas9> | SpyCas9 g-loxP2_C9 | This sgRNA targets the mTmG transgene | IDT | |
Mouse | SpyCas9> | TLR7-g2-REV | IDT | ||
Human | SpyCas9> | TRAC_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | TRAC_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | TRAC_site_03 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | TRAC_site_04 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | TRAC_site_05 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | TRBC1_site_01 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | TRBC1_site_02 | Targets endogenous human locus | lab IVT |
Show Experiments (1)
A novel human T cell platform to define biological adverse effects of genome editing
|
Human | SpyCas9> | g-11_C9 | sgRNA targeting CFTR exon 11 | IDT | |
Human | AsCas12a> | g-38330_C12a | gRNA targeting HPRT locus | IDT | |
Human | AsCas12a> | g-45_C12a | gRNA targeting CFTR inton-22-23 | IDT | |
Mouse | SpyCas9> | g-loxP2_C9 | This sgRNA targets the Ai9 and related transgenes | IDT | |
Mouse | AsCas12a> | g-loxPbot_C12a | This sgRNA targets the Ai9 and related transgenes at two sites | IDT | |
Rhesus macaque | SpyCas9> | gRNA #8 | IDT | ||
Human Mouse | SpyCas9> | sg298 | This sgRNA targets the Ai9 and related transgenes at multiple sites | Synthego |
Show Experiments (3)
Testing new LNPs (lipid nanoparticles) for delivery of Cas9 mRNA/sgRNA in primary fibroblast cells from adult Ai14 mouse cochlea
|
Mouse | SpyCas9> | sg298 | This sgRNA targets the Ai9 and related transgenes at multiple sites. 2'-O-Methyl at 3 first and last bases, 3' phosphorothioate bonds between first 3 and last 2 bases | Synthego | |
Human Mouse | SpyCas9> | sgAi9L | This sgRNA targets the Ai9 and related transgenes | IDT | |
sgAi9L | This sgRNA targets the Ai9 and related transgenes | ||||
Human Mouse | SpyCas9> | sgAi9R | This sgRNA targets the Ai9 and related transgenes | IDT |